Floatz logo

ab-1015

Ovarian Neoplasms

Arsenal Biosciences, Inc.Cell therapyPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

78 Active assets in the Ovarian Neoplasms cohort.

Asset / SponsorPhaseRating
Inno-206
GlaxoSmithKline
Phase 4BBB
Carboplatin
Eli Lilly and Company
Phase 3BB
gw786034
The Christie NHS Foundation Trust
Phase 2BB
tlk286
Telik
Phase 3BB
Niraparib
GlaxoSmithKline
Phase 4BB

View all 50 →

Same molecule, other indications

ab-1015 is also rated in:

ovarian carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
epithelial neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
ovarian disorderDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →